Cargando…

High-dose fulvestrant as third-line endocrine therapy for breast cancer metastasis to the left kidney: A case report and literature review

RATIONALE: Endocrine therapy plays an important role in the treatment of patients with hormone receptor-positive breast cancer. Renal metastasis of breast cancer is rare in clinical practice. PATIENT CONCERNS: We present here a 54-year-old woman with breast cancer after first line chemotherapy and s...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Dandan, Wang, Huiyu, Wang, Runjie, Liu, Chaoying, Xu, Junying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6023661/
https://www.ncbi.nlm.nih.gov/pubmed/29901634
http://dx.doi.org/10.1097/MD.0000000000011115
_version_ 1783335912354086912
author Xia, Dandan
Wang, Huiyu
Wang, Runjie
Liu, Chaoying
Xu, Junying
author_facet Xia, Dandan
Wang, Huiyu
Wang, Runjie
Liu, Chaoying
Xu, Junying
author_sort Xia, Dandan
collection PubMed
description RATIONALE: Endocrine therapy plays an important role in the treatment of patients with hormone receptor-positive breast cancer. Renal metastasis of breast cancer is rare in clinical practice. PATIENT CONCERNS: We present here a 54-year-old woman with breast cancer after first line chemotherapy and second line endocrinotherapy (i.e., toremifene & exemestane) failure. DIAGNOSES: The patient was rarely diagnosed breast cancer metastasis to the kidney and a positive hormone status (ER and PR) but was negative for human epidermal factor receptor 2 (HER2). INTERVENTIONS: The patient was treated with a high dose of fulvestrant (SERD; 500 mg) by intramuscular injection once per month. OUTCOMES: The patient's condition significantly improved as measured by a decrease in the renal and pulmonary masses; symptoms including dry cough and blood phlegm also improved. LESSONS: Endocrinotherapy with high-dose fulvestrant may provide benefits for patients with HR+/HER2− advanced breast cancer with renal metastasis after SERMs failure.
format Online
Article
Text
id pubmed-6023661
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-60236612018-07-03 High-dose fulvestrant as third-line endocrine therapy for breast cancer metastasis to the left kidney: A case report and literature review Xia, Dandan Wang, Huiyu Wang, Runjie Liu, Chaoying Xu, Junying Medicine (Baltimore) Research Article RATIONALE: Endocrine therapy plays an important role in the treatment of patients with hormone receptor-positive breast cancer. Renal metastasis of breast cancer is rare in clinical practice. PATIENT CONCERNS: We present here a 54-year-old woman with breast cancer after first line chemotherapy and second line endocrinotherapy (i.e., toremifene & exemestane) failure. DIAGNOSES: The patient was rarely diagnosed breast cancer metastasis to the kidney and a positive hormone status (ER and PR) but was negative for human epidermal factor receptor 2 (HER2). INTERVENTIONS: The patient was treated with a high dose of fulvestrant (SERD; 500 mg) by intramuscular injection once per month. OUTCOMES: The patient's condition significantly improved as measured by a decrease in the renal and pulmonary masses; symptoms including dry cough and blood phlegm also improved. LESSONS: Endocrinotherapy with high-dose fulvestrant may provide benefits for patients with HR+/HER2− advanced breast cancer with renal metastasis after SERMs failure. Wolters Kluwer Health 2018-06-15 /pmc/articles/PMC6023661/ /pubmed/29901634 http://dx.doi.org/10.1097/MD.0000000000011115 Text en Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle Research Article
Xia, Dandan
Wang, Huiyu
Wang, Runjie
Liu, Chaoying
Xu, Junying
High-dose fulvestrant as third-line endocrine therapy for breast cancer metastasis to the left kidney: A case report and literature review
title High-dose fulvestrant as third-line endocrine therapy for breast cancer metastasis to the left kidney: A case report and literature review
title_full High-dose fulvestrant as third-line endocrine therapy for breast cancer metastasis to the left kidney: A case report and literature review
title_fullStr High-dose fulvestrant as third-line endocrine therapy for breast cancer metastasis to the left kidney: A case report and literature review
title_full_unstemmed High-dose fulvestrant as third-line endocrine therapy for breast cancer metastasis to the left kidney: A case report and literature review
title_short High-dose fulvestrant as third-line endocrine therapy for breast cancer metastasis to the left kidney: A case report and literature review
title_sort high-dose fulvestrant as third-line endocrine therapy for breast cancer metastasis to the left kidney: a case report and literature review
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6023661/
https://www.ncbi.nlm.nih.gov/pubmed/29901634
http://dx.doi.org/10.1097/MD.0000000000011115
work_keys_str_mv AT xiadandan highdosefulvestrantasthirdlineendocrinetherapyforbreastcancermetastasistotheleftkidneyacasereportandliteraturereview
AT wanghuiyu highdosefulvestrantasthirdlineendocrinetherapyforbreastcancermetastasistotheleftkidneyacasereportandliteraturereview
AT wangrunjie highdosefulvestrantasthirdlineendocrinetherapyforbreastcancermetastasistotheleftkidneyacasereportandliteraturereview
AT liuchaoying highdosefulvestrantasthirdlineendocrinetherapyforbreastcancermetastasistotheleftkidneyacasereportandliteraturereview
AT xujunying highdosefulvestrantasthirdlineendocrinetherapyforbreastcancermetastasistotheleftkidneyacasereportandliteraturereview